<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Cardiac involvement in <z:e sem="disease" ids="C0036202" disease_type="Disease or Syndrome" abbrv="">sarcoidosis</z:e> is often silent and may lead to <z:hpo ids='HP_0001699'>sudden death</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>This study was designed to assess the value of programmed electric stimulation of the ventricle (PES) for risk stratification in patients with <z:e sem="disease" ids="C0036202" disease_type="Disease or Syndrome" abbrv="">sarcoidosis</z:e> and evidence of preclinical cardiac involvement on imaging studies </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: Patients with biopsy-proven systemic <z:e sem="disease" ids="C0036202" disease_type="Disease or Syndrome" abbrv="">sarcoidosis</z:e> but without cardiac symptoms who had evidence of <z:e sem="disease" ids="C0392077" disease_type="Disease or Syndrome" abbrv="">cardiac sarcoidosis</z:e> on <z:chebi fb="4" ids="30225">positron</z:chebi> emission tomography (PET) or cardiac MRI (CMR) were included </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients underwent baseline evaluation, echocardiographic assessment of left ventricular function, and programmed electric stimulation of the ventricle </plain></SENT>
<SENT sid="4" pm="."><plain>Patients were followed for survival and arrhythmic events </plain></SENT>
<SENT sid="5" pm="."><plain>Seventy-six patients underwent PES of the ventricle </plain></SENT>
<SENT sid="6" pm="."><plain>Eight (11%) were inducible for sustained <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> and received an implantable defibrillator </plain></SENT>
<SENT sid="7" pm="."><plain>None of the noninducible patients received a defibrillator </plain></SENT>
<SENT sid="8" pm="."><plain>Left ventricular ejection fraction was lower in patients with inducible <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo> (36.4±4.2% versus 55.8±1.5%, P&lt;0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>Over a median follow-up of 5 years, 6 of 8 patients in the group with inducible <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> had <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo> or died, compared with 1 <z:hpo ids='HP_0011420'>death</z:hpo> in the negative group (P&lt;0.0001) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: In patients with biopsy-proven <z:e sem="disease" ids="C0036202" disease_type="Disease or Syndrome" abbrv="">sarcoidosis</z:e> and evidence of cardiac involvement on PET or CMR alone, positive PES may help to identify patients at risk for <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>More importantly, patients in this cohort with a negative PES appear to have a benign course within the first several years following diagnosis </plain></SENT>
<SENT sid="12" pm="."><plain>PES may help to guide the use of implantable cardioverter defibrillators in this population </plain></SENT>
</text></document>